Virtually all glioblastomas treated in the first-line setting will recur in a short period of time,
and the search for alternative effective treatments has so far been unsuccessful. Various …

Abstract Isocitrate dehydrogenase (IDH) 1 or 2 mutations confer a favorable prognosis
compared to IDH-wildtype in astrocytoma, frequently denoting a lower grade malignancy …

Complete resection of isocitrate dehydrogenase 1 (IDH1)(R132H) glioma is unfeasible and
the classic post‐surgical chemo/radiotherapy suffers from high recurrence and low survival …

Oligodendrogliomas are defined at the molecular level by the presence of an IDH mutation
and codeletion of chromosomal arms 1p and 19q. In the past, case reports and small studies …

NAD+ is an essential cofactor metabolite and is the currency of metabolic transactions
critical for cell survival. Depending on tissue context and genotype, cancer cells have unique …

Background IDH-mutant diffuse gliomas are heterogeneous, and improved methods for
optimal patient therapeutic stratification are needed. PI3K/AKT/mTOR signaling activity can …

WHO 2016 classified glioblastomas into IDH-mutant and IDH-wildtype with the former
having a better prognosis but there was no study on IDH-mutant primary glioblastomas only …

Malignant neoplasms are characterized by poor therapeutic efficacy, high recurrence rate,
and extensive metastasis, leading to short survival. Previous methods for grouping …

The poor prognosis of triple‐negative breast cancer (TNBC) results from its high metastasis,
whereas inflammation accompanied by excessive reactive oxygen species (ROS) is prone …

Purpose: To investigate the toxicity profile and establish an optimal dosing schedule of
zotiraciclib with temozolomide in patients with recurrent high-grade astrocytoma. Patients …